Assessment of Clinically Related Outcomes and Biomarker Analysis for Translational Integration in Colorectal Cancer
ACROBATICC
Prospective, Population-based Cohort Collection of Blood Samples and Tumor Tissue From Patients Operated on for Primary or Metastatic Colorectal Cancer
1 other identifier
observational
1,200
1 country
1
Brief Summary
- A prospective, observational study on clinical outcomes of surgical management of primary and metastatic colorectal cancer
- Prospective collection of tissues to explore potential biomarkers in blood and/or primary or secondary cancers and/or normal colon
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2013
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2013
CompletedFirst Submitted
Initial submission to the registry
January 3, 2013
CompletedFirst Posted
Study publicly available on registry
January 8, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2035
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2036
April 30, 2026
April 1, 2026
23 years
January 3, 2013
April 25, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Cancer-specific survival
Time from surgery to death of cancer
5-years
Secondary Outcomes (1)
Recurrence-free survival
3 and 5 years
Study Arms (1)
open and laparoscopic surgery
Patients with primary and or metastatic colorectal cancer (CRC) eligible for curative surgery will be included. Subcohorts may be based on either colon cancer, rectal cancer, metastatic cancer, surgery (laparoscopy or open), node negative and node positive disease, and molecular profiling.
Interventions
Curative surgery for either primary (colorectal cancer, crc) or metastatic CRC (liver surgery)
Eligibility Criteria
All patients with colorectal cancer (primary and/or secondary) undergoing surgery for curative intent
You may qualify if:
- Diagnosis of colorectal cancer, primary or metastatic (liver), with a treatment intention of planned curative surgery
- Informed consent to participate
- Age ≥18
You may not qualify if:
- failure to provide written informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Stavanger University Hospital
Stavanger, 4068, Norway
Related Publications (10)
Soreide K, Watson MM, Lea D, Nordgard O, Soreide JA, Hagland HR; ACROBATICC collaborators. Assessment of clinically related outcomes and biomarker analysis for translational integration in colorectal cancer (ACROBATICC): study protocol for a population-based, consecutive cohort of surgically treated colorectal cancers and resected colorectal liver metastasis. J Transl Med. 2016 Jun 29;14(1):192. doi: 10.1186/s12967-016-0951-4.
PMID: 27357108BACKGROUNDHagland HR, Lea D, Watson MM, Soreide K. Correlation of Blood T-Cells to Intratumoural Density and Location of CD3+ and CD8+ T-Cells in Colorectal Cancer. Anticancer Res. 2017 Feb;37(2):675-683. doi: 10.21873/anticanres.11363.
PMID: 28179316RESULTWatson MM, Lea D, Hagland HR, Soreide K. Elevated Microsatellite Alterations at Selected Tetranucleotides (EMAST) Is Not Attributed to MSH3 Loss in Stage I-III Colon cancer: An Automated, Digitalized Assessment by Immunohistochemistry of Whole Slides and Hot Spots. Transl Oncol. 2019 Dec;12(12):1583-1588. doi: 10.1016/j.tranon.2019.08.009. Epub 2019 Oct 31.
PMID: 31677491RESULTWatson MM, Kanani A, Lea D, Khajavi RB, Soreide JA, Korner H, Hagland HR, Soreide K. Elevated Microsatellite Alterations at Selected Tetranucleotides (EMAST) in Colorectal Cancer is Associated with an Elderly, Frail Phenotype and Improved Recurrence-Free Survival. Ann Surg Oncol. 2020 Apr;27(4):1058-1067. doi: 10.1245/s10434-019-08048-6. Epub 2019 Nov 4.
PMID: 31686344RESULTLea D, Zaharia C, Soreide K. Programmed death ligand-1 (PD-L1) clone 22C3 expression in resected colorectal cancer as companion diagnostics for immune checkpoint inhibitor therapy: A comparison study and inter-rater agreement evaluation across proposed cut-offs and predictive (TPS, CPS and IC) scores. Cancer Treat Res Commun. 2024;38:100788. doi: 10.1016/j.ctarc.2023.100788. Epub 2023 Dec 22.
PMID: 38150845RESULTWatson MM, Lea D, Gudlaugsson E, Skaland I, Hagland HR, Soreide K. Prevalence of PD-L1 expression is associated with EMAST, density of peritumoral T-cells and recurrence-free survival in operable non-metastatic colorectal cancer. Cancer Immunol Immunother. 2020 Aug;69(8):1627-1637. doi: 10.1007/s00262-020-02573-0. Epub 2020 Apr 20.
PMID: 32314040RESULTVeen T, Kanani A, Alvestad AB, Edland KH, Lea D, Soreide K. Rectal cancer with synchronous liver metastasis undergoing hepatectomy: sequencing to the 'liver-first' reflects tumour burden of the primary. Surg Oncol. 2026 Mar 23;66:102413. doi: 10.1016/j.suronc.2026.102413. Online ahead of print.
PMID: 41886837RESULTVeen T, Lea D, Roalso M, Soreide K. Repeat hepatectomy for colorectal liver metastasis with rates of second and third hepatectomy: time-to-recurrence and overall survival in a population-derived cohort. HPB (Oxford). 2026 Feb;28(2):189-198. doi: 10.1016/j.hpb.2025.11.006. Epub 2025 Nov 14.
PMID: 41372018RESULTKanani A, Veen T, Lea D, Zaharia C, Watson M, Alexeeva M, Thorsen K, Soreide K. Neoadjuvant Immunotherapy Followed by Surgery Compared with Upfront Surgery Alone in Operable Colon Cancer with Deficient Mismatch Repair: Modeling Oncological Outcomes and Numbers Needed to Treat. Ann Surg Oncol. 2025 May;32(5):3068-3077. doi: 10.1245/s10434-024-16755-y. Epub 2024 Dec 30.
PMID: 39738901RESULTVeen T, Kanani A, Zaharia C, Lea D, Soreide K. Treatment-sequencing before and after index hepatectomy with either synchronous or metachronous colorectal liver metastasis: Comparison of recurrence risk, repeat hepatectomy and overall survival in a population-derived cohort. Eur J Surg Oncol. 2025 Feb;51(2):109540. doi: 10.1016/j.ejso.2024.109540. Epub 2024 Dec 9.
PMID: 39662106RESULT
Related Links
Biospecimen
Blood, whole blood, plasma, cancer tissue, normal tissue.
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Kjetil Søreide, MD, PhD, FRCS, FACS
Helse Stavanger HF
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER GOV
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 3, 2013
First Posted
January 8, 2013
Study Start
January 1, 2013
Primary Completion (Estimated)
December 31, 2035
Study Completion (Estimated)
December 31, 2036
Last Updated
April 30, 2026
Record last verified: 2026-04